Ray Dalio Royalty Pharma PLC Transaction History
Bridgewater Associates, LP
- $19.6 Billion
- Q1 2024
A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Royalty Pharma PLC stock. As of the latest transaction made, Bridgewater Associates, LP holds 371,462 shares of RPRX stock, worth $10.2 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
371,462
Previous 21,148
1656.49%
Holding current value
$10.2 Million
Previous $594,000
1799.16%
% of portfolio
0.06%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding RPRX
# of Institutions
395Shares Held
275MCall Options Held
276KPut Options Held
236K-
Morgan Stanley New York, NY44.2MShares$1.21 Billion0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA37.7MShares$1.03 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$581 Million0.02% of portfolio
-
Baillie Gifford & CO16.7MShares$457 Million0.4% of portfolio
-
Viking Global Investors LP11.5MShares$315 Million1.33% of portfolio
About Royalty Pharma plc
- Ticker RPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 437,139,008
- Market Cap $12B
- Description
- Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...